Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. Gamboni
P2.13-06 TP53 Status in Relation to Response to Anti-Alk Agents in Patients With EML4-ALK-Translocated NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P2.13-03 Real-Life Experience With Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Carcinoma of Unknown Primary With EML4‐ALK Fusion Response to ALK Inhibitors
Oncologist
Cancer Research
Medicine
Oncology
Variable Response to ALK Inhibitors in NSCLC With a Novel MYT1L-ALK Fusion
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
ALK (D5F3) CDx: An Immunohistochemistry Assay to Identify ALK-positive NSCLC Patients
Pharmacogenomics and Personalized Medicine
Molecular Medicine
Pharmacology
HER2 Regulates Cancer Stem-Like Cell Phenotype in ALK Translocated NSCLC
International Journal of Oncology
Cancer Research
Oncology
P2.13-07 CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
EMT Is Associated With, but Does Not Drive Resistance to ALK Inhibitors Among EML4-ALK Non-Small Cell Lung Cancer
Molecular Oncology
Cancer Research
Medicine
Oncology
Genetics
Molecular Medicine
Identification of Circulating Tumor Cells With EML4‑ALK Translocation Using Fluorescence In�situ Hybridization in Advanced ALK‑positive Patients With Lung Cancer
Oncology Letters
Cancer Research
Oncology
P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
